News for CytomX Therapeutics, Inc. (CTMX)

Piper Sandler has initiated coverage of CytomX Therapeutics (CTMX) with an optimistic outlook, assigning an Overweight rating to the stock. The investment firm

**media[572468]**

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

We recently compiled a list of the 10 Cheap Growth Stocks to Buy Now. In this article, we are going to take a look at where CytomX Therapeutics, Inc.

Cash, Cash Equivalents, and Investments: $100.6 million as of December 31, 2024.Revenue: $138.1 million for the full year 2024, up from $101.2 million in 2023.

Mar 06, 2025 / 10:00PM GMTOperator Good afternoon, everyone. Thank you for standing by. Welcome to the CytomX Therapeutics fourth-quarter 2024 and financial res

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Results Conference Call March 6, 2025 5:00 PM ETCompany ParticipantsChris Ogden - CFOSean McCarthy -...

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 210% and 89.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[559681]**

SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. ( CTMX), a leader in the field of masked, conditionally activated bi

CytomX Therapeutics Inc (CTMX) is set to release its Q4 2024 earnings on March 6, 2025. The consensus estimate for Q4 2024 revenue is $19.42 million, and the ea

CytomX Therapeutics (CTMX) stock slips as company announces staff reductions as part of a portfolio reorganization. Read more here.

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastat

CytomX Therapeutics (CTMX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. ( CTMX), a leader in the field of masked, conditionally activated bio

CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

CytomX stock touches 52-week low at $0.98 amid market challenges

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ETCompany ParticipantsChris Ogden - CFOSean A.